-
Revolu'onisingRou'neSepsisDiagnos'cs
-
Company Overview
Ø
Focusedonrapidassessmentofbloodstreaminfec'ondirectedtowardssepsisandthefightagainst‘superbugs’
Ø
14staffbasednearOxford(R&D,marke'ng)andCardiff(manufacturing,admin)
Ø
7patentfamiliesownedbyMomentum,onegrantedUS/EU;3licensedfromZEUSScien'ficnowbeingassigned
Ø
Fundedtodatethroughacombina'onofequityinvestorsandgrantstotaling£6.2m&£1.4mrespec'vely
Ø
ManualCognitor®MinusCEmarkedproductintroducedandgenera'ngdatatobuildmarketawareness
Mom
entumBioscienceLtd.Novem
ber2
016
-
The Problem
SepsiscoststheUShealthcare$20bnperyear
Sepsisclaimsmorelivesthananycancer
Sepsisaccountsfor1.6mUSadmissions
110mbloodculturestestsannually
90%ofbloodculturesresultsarenega've
Nega'vepa'entsremainonunnecessaryan'bio'csforup
to5days
Reducingtheuseofunnecessaryan2bio2csisakeyfeatureofgovernmentpolicyglobally.TheO’Neillreportspecificallyhighlightsrapiddiagnos2csasakeyrecommenda2on
Mom
entumBioscienceLtd.Novem
ber2
016
-
The Market
Othermicrobiologymethods
Tradi'onalBC:$0.9bn~3%growth
NucleicAcidbasedmolecular:$1.3bn
~8%growth
90%Nega'veBloodCulture
Confirmedat5days
10%BCposi've(7%infirst18hr,3%innext4days)
Nega'veBloodCulture
LateBC–3%
EarlyBC–7%
MicrobiologyMarket:$4.8bn~3.5%growth
TheautomatedCognitor®Systemaddressesthe93%ofpa2entswai2ngforposi2veiden2fica2onandnega2veconfirma2onthroughastrategyoftargetedadop2on
Effec2vepa2entmanagementcurrentlyremainslimitedbylengthy2metoresultofbloodculture
Notto
scale;B
C=Bloo
dCu
lture
Mom
entumBioscienceLtd.Novem
ber2
016
Cognitor®reportsnega'vesandslowgrowingposi'vesin
-
Sampleclean-up:Followingsamplelysis,residual
enzymesoutsidethetargetmicro-organismsareinactivated.
Microbial
lysis:Targetmicro-organismsarelysed.DNA-modifyingenzymes,
includingDNApolymerase,are
released.
Substratemodification:TheDNA-modifyingenzymesareincubatedwithsyntheticDNA
substrate.Thisisthenmodifiedtocreateatemplate
forPCR.
PCRtemplate:Thisisamplified&measuredusingqPCR.Ifthereare
nomicro-organisms
present,thePCRtargetwillnotbecreatedand
amplificationwillnotoccur.
Specimen:Suspectedofcontaining
bacteriaor fungi
The Technology: ETGA
ETGAisabletocombinethespeedandsensi'vityofPCRwiththe
universalnatureofbloodculture
Enzyma'cTemplateGenera'onandAmplifica'onThespeed&sensi7vityofPCRwiththeuniversalnatureofbloodculture
Asuperiorlimitofdetec'on(1,000–10,000x)comparedtobloodculture
allowsCognitor®topickupinfec'onsbloodculturemisses
Furtherapplica'onsincludedifferen'a'onandcategorisa'onof
posi'vepathogensandan'microbialsuscep'bilitytes'ng
Momentumownspatentscoveringthedetec2onofbacteria&fungi,theabsenceofmicroorganisms&detec2onofviableorganisms.
Mom
entumBioscienceLtd.Novem
ber2
016
-
The Pa>entsMom
entumBioscienceLtd.Novem
ber2
016
EarlyOnsetSepsisinNeonates• Avoidtoxican'bio'cs•
Getmotherandbabyhomeearly• MeetNICEguidelines
AdultIntensiveCare• Significantcri'calcarecosts•
Reducespa'entburden• Supportsstewardshipini'a'ves
TrialData:- Sheffield:124Neonates- Basingstoke&
Winchester:246pa'ents
- UCLH:AdultICU
- AlderHey:PaediatricOncology/Haematology
Acomprehensivetrialplantoincludehealtheconomicswillsupportarapidadop2onstrategyoftheautomatedCognitor®System
-
The Strategy
Ø Focus:Earlyonsetsepsisinneonatesandpa'entsin
Ø
Automate:TheCognitor®Systemwillrunupto18tests/dayinasingleshim
Ø
Demonstrate:Clinical&economicu'lityintargetedpa'entgroups
Ø
Scale-up:AchieveFDA510(k)clearance&CEMarkin2019forautoma'on
Throughfocusandtargetedadop2on,Momentumisabletodevelopkeydata,generatesupportfromKOLsandbuildastrongplaNormforcon2nuedgrowth
Mom
entumBioscienceLtd.Novem
ber2
016
EarlierAdoption
LaterAdoption
Earlyonsetsepsisinneonates
Intensivecareunits
GeneralMedicalwardswithselectively
improvingpatients
Othermedical/surgicalwards
HigherMedical
Need
Increased
Savings
BCTe
stsperfo
rmedann
ually(U
SA,UK,France,German
y,SpainNe
therland
s)
Ratio
nale
1.1M
7.0M
9.0M
>10.0M
Preventa2nd doseoftoxic
gentamicin at36hrsandgetmotherandbabyhomesooner
Preventover-useofantibiotics
andassociatedmultidrugresistance
EarlydischargeandIVtooral
antibioticswitch
Includesoncology,otherpaediatrics
&surgicalpatients includingthosegroupsat
lowriskofinfection
Momentum CommercialAdoption Pyramid
-
Contact:SumiThaker,[email protected]+447464606666
